On these bases, in a murine ovarian cancer model Higuchi and colleagues [58] demonstrated that the CTLA-4 antibody, but not the inhibition of the PD-1/PD-L1 pathway, synergize with PARP-inhibitors increasing long term survival in the majority of mice (p < 0.0001). Here, CTLA4 is linked to ovarian carcinoma.